Industry Goes On Offensive Against Prescription Pseudoephedrine Trend
This article was originally published in The Tan Sheet
Executive Summary
Drug firms hope to dissuade states from moving drugs that contain methamphetamine precursors to prescription status by funding electronic systems to track nonprescription sales of the products
You may also be interested in...
Tennessee Emerges As PSE Battleground With Rx, NPLEx Proposals
The conflict between electronic tracking of pseudoephedrine purchases and shifting the drug ingredient to prescription-only status is elevated in Tennessee as lawmakers offer bills for both anti-methamphetamine strategies.
Industry Must Adapt To Emerging Trends That Threaten Recent Economic Gain
The OTC industry must adapt to evolving market trends as the global economy recovers in order to maintain the market share it gained during the recession, said experts at a European industry conference
Senate Meth Fight Pits Rx-Only Pseudoephedrine Against E-Tracking Option
The debate over how best to keep methamphetamine precursors from diversion to illicit drug labs is coming to a head as lawmakers stake out positions and legislation to restrict nonprescription access to pseudoephedrine waits in the wings